GERN

GeronC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$2.20

Analysis reference price unavailable

Analysis 2026-08-01 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$1.30

Analysis reference price unavailable

Analysis 2026-08-01 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$0.70

Analysis reference price unavailable

Analysis 2026-08-01 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-08-01

AI commentary

This is a cautious monitoring view. Recent-news and social aggregates are absent, analyst-target count and revision data are unavailable, and the next company-announced event is the August 5 earnings release. The deterministic prior is negative, with expected returns of -1.11% over 5 days, -3.18% over 20 days and -5.09% over 60 days; the upcoming print could change the thesis, but missing consensus and market-reaction data limit confidence.

RankAlpha Sentiment Codex - 2026-08-01

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-08-05eventQ2 2026 results and RYTELO execution checkpointHigh impact

Geron announced that it plans to report second-quarter 2026 results and business highlights before market open on August 5, 2026. The print should test progress from Q1 RYTELO net product revenue of $51.8 million and the reiterated full-year guidance range of $220 million-$240 million [#PR-EARNINGS-2026-07-22] ([company IR](https://ir.geron.com/)).

2026-10-16eventRYTELO clinical and real-world evidence updatesHigh impact

Geron expects initial second-half 2026 data from investigator-sponsored and real-world studies, while advancing the pivotal Phase 3 IMpactMF trial in relapsed/refractory myelofibrosis. Positive evidence could broaden the RYTELO narrative, but timing and outcomes remain uncertain [#IR-2026-05-06] ([Q1 2026 release](https://ir.geron.com/news-releases/news-release-details/geron-corporation-reports-first-quarter-2026-financial-results)).

2026-12-31catalystEuropean commercialization strategy updateHigh impact

Management plans to provide an update on European commercial plans by year-end 2026 while pursuing pathways to bring RYTELO to patients outside the United States. A credible strategy could expand the opportunity, but execution and market-access visibility remain limited [#IR-2026-05-06][#IR-2026-01-12].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-08-01 • Updated nightlySource: Internal modelMethodology